Showing 5021-5030 of 20470 results for "".
- ECHO Cohort: Maternal Smoking in Pregnancy Linked to Higher Childhood BPhttps://reachmd.com/news/echo-cohort-maternal-smoking-in-pregnancy-linked-to-higher-childhood-bp/2485732/Recent research describes an association between maternal smoking during pregnancy (MSDP) and higher diastolic blood pressure and increased risk
- KALOS and LOGOS Data: Lung Function and Exacerbation Findingshttps://reachmd.com/news/kalos-logos-data-lung-function-exacerbation/2485730/AstraZeneca reports that a pooled Phase III analysis in uncontrolled asthma found lung function improvements with single-inhaler triple therapy
- BE RADIANT: Bimekizumab Delivers Durable Plaque PsO Gains Through 3 Yearshttps://reachmd.com/news/be-radiant-bimekizumab-delivers-durable-pro-gains-through-3-years/2485749/Bimekizumab treatment was associated with rapid and sustained improvements in patient-reported outcomes (PROs) among adults with moderate to seve
- Octane Aesthetics Tech Forum: Strategy Over Syringes Leads 2025 Filler Reboundhttps://reachmd.com/news/octane-aesthetics-tech-forum-strategy-over-syringes-leads-2025-filler-rebound/2485717/“Flipping the Filler Script” was a hot topic at the 2026 Octane Aesthetics Tech Forum held January 8 and 9 in Newport Beach, California. The panel was moderated by Jason D. Bloom, MD, FACS, of Bloom Facial Plastic Surgery in Bryn Mawr, Pennsylvania, and panelists included Shawna Chrisman, NP, Chi
- Adaptive Molecular Subtyping in Treated Breast Cancer: Reporting Paired Tissue and Plasma Findingshttps://reachmd.com/news/adaptive-molecular-subtyping-in-treated-breast-cancer-reporting-paired-tissue-and-plasma-findings/2485708/In a single-center, retrospective cohort of 32 patients, investigators reported therapy-associated biomarker and genomic shifts seen through longitudinal
- TOGETHER-PsO: Combination Therapy Links Obesity Treatment to Psoriasis Clearancehttps://reachmd.com/news/together-pso-trial-links-obesity-treatment-to-enhanced-psoriasis-clearance/2485716/New data show that a combination therapy of ixekizumab (Taltz) plus tirzepatide (Zepbound) was superior to ixekizumab alone for achieving PASI 100 and ≥10% weight loss at 36 weeks in adults with moderate-to-severe plaque psoriasis. The phase 3b TOGETHER-PsO
- Computational validation of a CDS tool for LAI‑PrEP bridge‑period navigationhttps://reachmd.com/news/computational-validation-of-a-cds-tool-for-laiprep-bridgeperiod-navigation/2485684/A modeling paper reports computational validation of a configurable clinical decision support (CDS) tool described as a LAI‑PrEP bridge‑period CDS algorithm intended to r
- Semaglutide and NAION in US Veterans: Observational Safety Signalhttps://reachmd.com/news/semaglutide-and-naion-in-us-veterans-observational-safety-signal/2485682/Using Veterans Health Administration data, investigators reported a target-trial emulation examining whether semaglutide initiation
- Columbia Researchers Share New Data on Maternal Mortalityhttps://reachmd.com/news/new-data-maternal-mortality/2485680/Investigators analyzing U.S. maternal mortality reported that accidental drug overdose, homicide, and suicide were the leading causes of death among pregnant and postpartum women.
- Sleep‑Aligned Overnight Fasting and Cardiometabolic Functionhttps://reachmd.com/news/overnight-fasting-cardiometabolic-function/2485673/A sleep-wake-aligned extension of overnight fasting was reported to shift several cardiometabolic biomarkers over a short intervention